BREAKING ADVANCES

4007  Highlights from Recent Cancer Literature

OBITUARY

4009  Donald Lee Morton: In Memoriam (1934–2014)
Dave S.B. Hoon

REVIEWS

4011  Role of the Neural Niche in Brain Metastatic Cancer
John Termini, Josh Neman, and Rahul Jandial

4016  Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Christos Hatzis, Philippe L. Bedard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming Shi, Robert Clarke, John Quackenbush, and Benjamin Haibe-Kains

PERSPECTIVE

4024  The Increasing Urgency for Standards in Basic Biologic Research
Leonard P. Freedman and James Inglese

MICROENVIRONMENT AND IMMUNOLOGY

4030  Microbiota Modulate Tumoral Immune Surveillance in Lung through a γδT17 Immune Cell-Dependent Mechanism
Min Cheng, Liting Qian, Guodong Shen, Geng Bian, Tingjuan Xu, Weiping Xu, Gan Shen, and Shilian Hu

MOLECULAR AND CELLULAR PATHOBIOLOGY

4053  GPER Mediates Activation of HIF1α/VEGF Signaling by Estrogens
Ernestina Marianna De Francesco, Michele Pellegrino, Maria Francesca Santolla, Rosamaria Lappano, Emilia Ricchio, Sergio Abonante, and Marcello Maggiolini

PREVENTION AND EPIDEMIOLOGY

4065  Recent Prediagnostic Aspirin Use, Lymph Node Involvement, and 5-Year Mortality in Women with Stage I–III Breast Cancer: A Nationwide Population-Based Cohort Study
Thomas I. Barron, Evelyn M. Flahavan, Linda Sharp, Kathleen Bennett, and Kala Visvanathan

4078  Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age
Elisabeth F. Beaber, Diana S.M. Buist, William E. Barlow, Kathleen E. Malone, Susan D. Reed, and Christopher I. Li

Precis: Breast cancer risk appears to be increased by recent use of contemporary oral contraceptives, with some variation in this risk possibly associated with different formulations.

Precis: This study offers a preclinical rationale for coadministering immune checkpoint therapies with cancer vaccines to vastly empower their efficacy, with major implications for the broader and more effective application of active immunotherapy in treating malignancy.

Precis: These findings demonstrate the importance of commensal bacteria in supporting the host immune response against cancer in mucosal tissues and also suggest deleterious effects of antibiotic treatment on cancer susceptibility and progression.
4090 Telomere Length in White Blood Cell DNA and Lung Cancer: A Pooled Analysis of Three Prospective Cohorts
Wei Jie Seow, Richard M. Cawthon, Mark P. Purdie, Wei Hu, Yu-Tang Gao, Wen-Yi Huang, Stephanie J. Weinstein, Bu-Tian Ji, Jarmo Virtamo, H. Dean Hosgood III, Bryan A. Bassig, Xiao-Ou Shu, Qiuying Cai, Yong-Bing Xiang, Shen Min, Wong-Ho Chow, Sonja I. Berndt, Christopher Kim, Unhee Lim, Demetrius Albanes, Neil E. Caporaso, Stephen Chanock, Wei Zheng, Nathaniel Rothman, and Qing Lan
**Précis:** Positive associations between telomere length in white blood cells and risk of lung cancer open an interesting new perspective on how immune cell alterations may affect susceptibility to this type of cancer.

**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

4099 Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer
Robert T. Dauchy, Shulin Xiang, Lulu Mao, Samantha Brimer, Melissa A. Wren, Lin Yuan, Muralidharan Anbalagan, Adam Hauch, Tripp Frasch, Brian G. Rowan, David E. Blask, and Steven M. Hill
**Précis:** Striking demonstrations in a preclinical model of estrogen-dependent breast cancer show how disrupting normal circadian patterns of melatonin production by exposure to light at night can cause resistance to tamoxifen therapy.

4111 Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolytic Kinetics and Tumor Viability
**Précis:** Methods to image the replication cycles of oncolytic viruses noninvasively in vivo will assist the clinical development of this class of experimental therapeutics by helping identify virus expansion during dose escalation studies.

4122 Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel III, Edward J. Hartsough, Michael A. Davies, Yulius Y. Setiady, and Andrew E. Aplin
**Précis:** This study provides a preclinical rationale to combine a RAF inhibitor with an ERBB3/HER3-neutralizing antibody to improve durable therapeutic responses in melanomas harboring BRAF V600E mutations.

4133 Engineered Fusokine GIF4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Jiusheng Deng, Shala Yuan, Andrea Pennati, Jordan Murphy, Jian Hui Wu, David Lawson, and Jacques Galipeau
**Précis:** This preclinical study introduces a chimeric cytokine composed of GM-CSF and IL4 that is a powerful inducer of melanoma-eradicating B cells, suggesting its candidacy as a novel immunotherapeutic tool and revealing a previously unrecognized potential for B cells in melanoma immunotherapy.

4145 miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1
Roberto Dinami, Cristiana Ercolani, Eleonora Petti, Silvano Piazza, Yari Ciani, Rosanna Sestito, Andrea Sacconi, Francesca Biaigioni, Carlos Le Sage, Reuven Agami, Roberta Benetti, Marcella Motolese, Claudio Schneider, Giovanni Blandino, and Stefan Schoeftner
**Précis:** These findings highlight an miRNA-mediated mechanism for controlling telomere function, suggesting the existence of a class of "telo-miRNAs" with an impact on cancer and aging.

4157 An Inducible Hepatocellular Carcinoma Model for Preclinical Evaluation of Antiangiogenic Therapy in Adult Mice
Anja Runge, Junhao Hu, Matthias Wieland, Jann-Philip Bergeest, Carolin Mogler, André Neumann, Cyrill Géraud, Bernd Arnold, Karl Rohr, Dorde Komljenovic, Peter Schirmacher, Sergi Goerdot, and Hellmut G. Augustin
**Précis:** This study validates a versatile inducible model of hepatocellular carcinoma (HCC) in adult mice for the study of multinodular HCC tumorigenesis and response to therapy during tumor progression.

4170 Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties
**Précis:** The findings of this study identify YAP1-driven SOX9 expression as a critical event in acquisition of CSC properties in nontransformed cells and esophageal cancer cells and suggest that pharmacologic inhibition of YAP1 may be an effective means of targeting the CSC population.
miRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells

Min Jin, Tao Zhang, Can Liu, Mark A. Badeaux, Bigang Liu, Ruifang Liu, Collene Jeter, Xin Chen, Alexander V. Vlassov, and Dean G. Tang

*Précis:* These results define a tumor suppressor function for an miRNA that limits prostate cancer by blocking the properties of cancer stem-like cells in that setting, with potential implications to improve the treatment of recurrent disease driven by these cells.

ABCB5 Maintains Melanoma-Initiating Cells through a Proinflammatory Cytokine Signaling Circuit

Brian J. Wilson, Karim R. Saab, Jie Ma, Tobias Schatton, Pablo Pütz, Qian Zhan, George F. Murphy, Martin Gasser, Ana Maria Waaga-Gasser, Natasha Y. Frank, and Markus H. Frank

*Précis:* These findings define a novel function for a drug efflux transporter molecule in cancer stem-like cell maintenance, possibly explaining its broad overexpression in many types of human cancer.

CORRECTION

Correction: Potentiation of the Novel Topoisomerase I Inhibitor Indenoisoquinoline LMP-400 by the Cell Checkpoint and Chk1-Chk2 Inhibitor AZD7762

ABOUT THE COVER

Induced PDL1 expression in the tumor microenvironment can be abrogated with neutralizing antibodies against IFNγ. In the B16 model, TLR4/7/8 agonists-formulated tumor vaccine increased antitumor CTL response that correlated with increased tumor infiltrating T cells and increased PDL1 expression in the tumor microenvironment. This induction of PDL1 was found to be IFNγ dependent as shown. When combining PDL1-inducing vaccine with PDL1 blocking antibody, regression of established tumors was found. For details, see article by Fu and colleagues on page 4042.